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Abstract: Of 1614 Nordic children with ALL that were treated according to the NOPHO ALL92 
protocol, 20 developed an SMN (cumulative risk at 12 years: 1.6%). Sixteen of the twenty SMNs 
were acute myeloid leukemias or myelodysplasias
7q deletions (n=2). In Cox multivariate analysis longer duration of oral MTX/6MP maintenance 
therapy  (p=0.02;  being  longest  for  standard  risk  patients)  and  presence  of  high
(p=0.07) were related to an increased risk of SMN. In 524 patients we determined the erythrocyte 
activity of thiopurine methyltransferase (TPMT), which methylates 6MP and its metabolites, and 
thus  reduces  cellular  levels  of  cytotoxic  6
significantly lower in those that did compared to 
vs 18.1 IU/ml; p=0.02). Among 427 TPMT wild type patients, those who developed SMN received 
higher 6MP doses than the remaining (69.7 vs 60.4 mg/m
levels  of  methylated  metabolites  that  inhibit  purine 
incorporation of 6-thioguanine nucleotides into DNA. In conclusion, the duration and intensity of 
6MP/MTX maintenance therapy of child
Introduction: One  of  the  most  devastating 
complications  to  the  therapy  of  childhood  acute 
lymphoblastic leukemia (ALL) is the development of 
second cancers (SMN), a complication that in general 
has a poor prognosis.
1-5 Although on average it occurs 
in 2% of all patients depending on the therapy given, 
the  published  cumulative  incidences  vary  from  less 
than  1%  to  almost  10%.
6-8 Furthermore,  since  the 
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Of 1614 Nordic children with ALL that were treated according to the NOPHO ALL92 
protocol, 20 developed an SMN (cumulative risk at 12 years: 1.6%). Sixteen of the twenty SMNs 
were acute myeloid leukemias or myelodysplasias, and 9 of these had either monosomy 7 (n=7) or 
7q deletions (n=2). In Cox multivariate analysis longer duration of oral MTX/6MP maintenance 
therapy  (p=0.02;  being  longest  for  standard  risk  patients)  and  presence  of  high
to an increased risk of SMN. In 524 patients we determined the erythrocyte 
activity of thiopurine methyltransferase (TPMT), which methylates 6MP and its metabolites, and 
thus  reduces  cellular  levels  of  cytotoxic  6-thioguanine  nucleotides.  The  TPMT  activit
in those that did compared to those that did not develop a
. Among 427 TPMT wild type patients, those who developed SMN received 
higher 6MP doses than the remaining (69.7 vs 60.4 mg/m
2, p=0.03), which may reflect increased 
levels  of  methylated  metabolites  that  inhibit  purine  de  novo  synthesis  and  thus  enhance 
thioguanine nucleotides into DNA. In conclusion, the duration and intensity of 
6MP/MTX maintenance therapy of childhood ALL may influence the risk of SMN.
One  of  the  most  devastating 
complications  to  the  therapy  of  childhood  acute 
(ALL) is the development of 
second cancers (SMN), a complication that in general 
average it occurs 
in 2% of all patients depending on the therapy given, 
the  published  cumulative  incidences  vary  from  less 
Furthermore,  since  the 
overall  survival  of  childhood  ALL  now  approaches 
85%, SMN now encompass 15
childhood ALL therapy. 
The incidence of SMN will be influenced not only 
by  the  treatment  modalities  applied  but  also  by  the 
duration of follow-up, since SMN may emerge several 
decades from the initial ALL treatment. Furthermore, 
some  centres  actively  screen  for  subclinical  cancers,
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
Neoplasms After Treatment for Pediatric 
Faculty of Medicine, Institute of Gynecology, Obstetrics and Pediatrics, and the Department of Pediatrics, the 
Kjeld Schmiegelow, professor M.D., Dr.Med.Sci., The Department of Pediatrics, The Juliane Marie 
Center 5704, University Hospital Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark. Telephone: +45 3545 1357, 
the  Creative  Commons  Attribution  License
which permits unrestricted use, distribution, and reproduction in any medium, 
Of 1614 Nordic children with ALL that were treated according to the NOPHO ALL92 
protocol, 20 developed an SMN (cumulative risk at 12 years: 1.6%). Sixteen of the twenty SMNs 
, and 9 of these had either monosomy 7 (n=7) or 
7q deletions (n=2). In Cox multivariate analysis longer duration of oral MTX/6MP maintenance 
therapy  (p=0.02;  being  longest  for  standard  risk  patients)  and  presence  of  high-hyperdiploidy 
to an increased risk of SMN. In 524 patients we determined the erythrocyte 
activity of thiopurine methyltransferase (TPMT), which methylates 6MP and its metabolites, and 
thioguanine  nucleotides.  The  TPMT  activity was 
those that did not develop an SMN (Median: 12.1 
. Among 427 TPMT wild type patients, those who developed SMN received 
.03), which may reflect increased 
synthesis  and  thus  enhance 
thioguanine nucleotides into DNA. In conclusion, the duration and intensity of 
hood ALL may influence the risk of SMN.
overall  survival  of  childhood  ALL  now  approaches 
85%, SMN now encompass 15-20% of all deaths after 
incidence of SMN will be influenced not only 
by  the  treatment  modalities  applied  but  also  by  the 
up, since SMN may emerge several 
decades from the initial ALL treatment. Furthermore, 
some  centres  actively  screen  for  subclinical  cancers,Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure 1: Pattern and incidence of second neoplasms (SMN) among Nordic patients treated during four consecutive Nordic protocol periods. 
Numbers at the top of columns are the total number of SMNs in that protocol period. CNS = central nervous system; Rtx = radiotherapy; 
AML = acute myeloid leukemia; MDS = myelodysplaisa. 
e.g. meningeomas
9 and thyroid cancers.
10 Finally, the 
strategies or reporting of SMNs differ widely between 
collaborative groups ranging from no-news-are-good-
news  to  follow-up  by  regular  questionnaires  or 
systematic exchange of data with national or regional 
cancer  registries,  which  in  the  Nordic  countries  are 
population-based  and  enforced  by  legislation  and  by 
exchange of data with the National hospital discharge
registration. 
Treatment-related  risk  factor  analyses  have 
primarily focused on irradiation, alkylating agents, and 
topoisomerase  II  inhibitors  (anthracyclines, 
epipodophyllotoxins)  that  induce  DNA  damage, 
whereas  less  attention  has  been  paid  to  mechanisms 
that interfere with DNA control, including drugs that 
may  modify  DNA  repair.
5 Previously,  children  with 
higher risk ALL had the highest risk of SMN due to 
their  more  intensive  chemotherapy  and  radiotherapy 
and the use of hematopoietic stem cell transplantation. 
However,  studies  from  the  Nordic  Society  for 
Paediatric Haematology and Oncology (NOPHO) and 
from  St  Jude  Children’s  Research  Hospital  have 
indicated that even the less intensive 6-mercaptopurine 
(6MP)/methotrexate (MTX) maintenance therapy may 
enhance  the  risk of  SMN not  least for  patients with 
thiopurine  methyltransferase  (TPMT)  low-activity 
polymorphisms.
11,12 Since TPMT methylates 6MP and 
some  of  its  metabolites  and  thus  reduces  the 
intracellular  amounts  of  cytotoxic  6-thioguanine 
nucleotides (6TGN) available for DNA incorporation, 
the  5-10% of  patients who have low  TPMT  activity 
will  have higher  intracellular  6TGN levels for  DNA 
incorporation and DNA damage. 
Based  on  these  findings,  the  predominance  of 
therapy-related  acute  myeloid  leukemia  and
myelodysplasia (t-AML/MDS) in the two most recent 
Nordic ALL protocols (Figure 1), and since 75% of 
the SMNs occurred among standard risk patients, we 
analyzed  in  depth  the  occurrence  of  SMN  in  the 
NOPHO ALL92 by taking advantage of an extensive 
registration of individual data on maintenance therapy 
during the first years of the protocol. 
Patients and Methods: Patients: From January 1992 
until October 2001, 1614 children 1.0-14.9 years of age 
were diagnosed with B-cell precursor or T-cell ALL in 
the  Nordic  countries  (Denmark,  Finland,  Iceland, 
Norway, and Sweden) and were treated according to 
the NOPHO ALL92 protocol.
8
Risk grouping: The risk group criteria are given in 
table 1.
13 The patients who had higher risk features at 
diagnosis  and  were  assigned  to  the  very  high  risk Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
(VHR)  treatment  arm  received  prophylactic  or 
therapeutic central nervous system (CNS) irradiation as 
well  as  LSA2L2 instead  of  MTX/6MP  maintenance 
therapy.
14
Induction  therapy  and  consolidation  therapy have 
previously been published in detail.
13
CNS irradiation and stem cell transplantation: Due 
to CNS disease at diagnosis or allocation to the very 
high risk  protocol arm  123  non-transplanted  patients 
(7.6% of the total study population) received cranial 
irradiation in 1
st remission (CR1). 31 boys and 21 girls 
with higher-risk criteria received a hematopoitetic stem 
cell transplantation in CR1.
15
Oral 6MP/MTX maintenance therapy was initiated 
at  treatment  week  13  (standard  risk,  SR),  32 
(intermediate  risk,  IR),  or  63  (high  risk,  HR)  and 
scheduled to continue until 2 years (IR and HR) or 2½ 
years  (SR)  after  diagnosis. Between  1992  and 1996, 
538 patients with SR-, IR-, or HR-ALL were included 
in the randomised ALL-92 maintenance therapy trial.
16
As part of that study we registered all data on MTX 
and 6MP doses as well as all blood counts (28.000 data 
sets in total), and furthermore added data on MTX and 
6MP  dosing  and  blood  counts  during  maintenance 
therapy  for  the  patients  with  SMN  that  were  not 
included in the randomised study. The genotype (low 
activity  polymorphisms  G460A  and  A719G)  and/or 
erythrocyte  TPMT  activity  was  available  for  609 
patients.
17 Erythrocyte  TPMT  activity  was  measured 
during maintenance therapy and at least 8 weeks from 
the  last  red  blood  cell  transfusion. For  484  of  these 
patients  only  the  erythrocyte  TPMT  activity  was 
available.  The  antimode  of  the  TPMT  activity 
distribution  was  14  IU/ml,  and  patients  with  TPMT 
below  that  level, and  for  whom no  TPMT  genotype 
was  available,  were  classified  as  TPMT  presumed 
heterozygous.
Results and Discussion: With a median follow-up of 
10.4 years for patients who remain in first remission, a 
total of 20 patients developed an SMN at a median of 
3.4 years from the diagnosis of ALL (risk at 12 years: 
1.6%)  (Table  1).  The  12-year  cumulative  risk  of 
developing an SMN (pSMN12y) was 1.6 +/- 0.4%. The 
projected  risk  of  SMN  among  the  non-transplanted 
patients was significantly related to the risk group and 
was 2.4 +/- 0.7% for SR-ALL, 1.2 +/- 0.7% for IR-
ALL, and 0.3 +/- 0.3% for higher risk ALL patients 
(p=0.007)  (Table  1).  The  cumulative  risk  of 
developing  SMN  was  1.7  +/- 0.4%  for  the  1316 
patients  who  were  in  CR1  when  they  initiated 
MTX/6MP  maintenance  therapy  vs  0%  for  the  169 
patients  in  CR1  at  the  start  of  LSA2L2 maintenance 
therapy. Twelve of the 20 SMN patients died within 21 
months from diagnosis  of their SMN with  a median 
time to death of 8.8 months and a projected survival of 
39% +/- 11%. 
Sixteen  of  the  twenty  SMNs  were  t-AML/MDS, 
and  9  of  these  had  either  monosomy  7  (n=7)  or  7q 
deletions (n=2). Eight of the nine -7/7q- t-AML/MDS 
cases occurred among patients with high-hyperdiploidy 
(n=4),  t(12;21)(p13;q22)  (n=1),  or  a  normal/missing 
(n=4) karyotype at diagnosis of ALL, which indicates a 
biological propensity for non-disjunction, although the 
results  did  not  reach  statistical  significance.  In  Cox 
multivariate  analysis,  longer  duration  of  oral 
MTX/6MP maintenance therapy (p=0.02; being longest 
for  standard  risk  patients)  and  presence  of  high-
hyperdiploidy (p=0.07) were related to increased risk 
of  SMN.  Among  all  562  SR-ALL  patients,  the  161 
patients with a high-hyperdiploid karyotype had a 4.8 
+/- 1.8% risk of developing SMN compared to a 1.5 
+/- 0.6%  risk  for  the  remaining  401  SR  patients 
(p=0.02). 
The  patients  who  developed  an  SMN  had 
significantly lower TPMT activity than the remaining 
patients  (Median:  12.1  vs  18.1  IU/ml;  p=0.02),  and 
they  received  10-15%  higher  6MP  doses  than  those 
that did not develop an SMN, and this was the case 
both among patients classified as TPMT low activity 
(Median: 55.5 (N=3) vs 50.3 mg/m
2 (N=57); p=0.31) 
and those classified as TPMT wild type (Median: 69.7 
(N=9) vs 60.4 mg/m
2 (N=418); p=0.03). The positive 
relation between 6MP dosage and risk of SMN is likely 
to reflect that TPMT-mediated thiopurine methylation, 
not  least  through  6-methyl-thioinosine  5'-
monophosphate,  will  inhibit  purine  de  novo 
synthesis,
18 and  since  6-methyl-thioinosine  5'-
monophosphate  levels  preferentially  increase  with 
upward  dose  adjustments  of  6MP,
19 this  may  cause 
enhanced  DNA-6TGN  incorporation.  Such  a 
relationship is supported by the recent demonstration 
of a positive correlation between erythrocyte levels of 
methylated 6MP metabolites versus the index between 
DNA-6-thioguanine nucleotide levels in nucleated cells 
and  the  erythrocyte  levels  of  6-thioguanine 
nucleotides.
20
Several drugs have been suggested to  modify the 
risk of SMN by promoting the growth of a malignant 
clone or by interference with DNA-repair. Such agents 
include granulocyte colony stimulating factor (),
21 L-
asparaginase,
22 and  thiopurines.
11,23,24 The  present 
population-based,  retrospective  study  strongly 
indicates that maintenance therapy, and especially 6MP 
pharmacotherapy,  influenced  the  development  of 
SMNs, since 6MP can cause DNA damage,
25-27 and the 
risk of t-AML/MDS was related to i) longer duration of 
6MP/MTX  maintenance  therapy,  ii)  low  TPMT 
activity, and iii) significantly higher doses of 6MP for 
TPMT  wild  type  patients.  During  oral  6MP  therapyMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 1. Risk group, therapy, and second malignant neoplasms in NOPHO ALL-92 protocol
SR-ALL IR-ALL HR-ALL VHR-ALL
Risk criteria


















M3 d15 or M2/3 d29,
no VHR-criteria
HR-ALL at diagnosis & age ≥5y &
i) CNS leukemia, or
ii) lymphomatous leukemia, or
iii) d15 M3 or a d29 M2/3 BM, or
iv) T-ALL with >1 other HR-features
Patients 562 590 239 223
Doxorubicin/daunomycin
1 120 240 280 400
Cyclophosphamide
1 0 3.000 3.000 6.600
Cranial irradiation No No No Yes
6MP/MTX (weeks) 117 72 41 0-8
Dead in CR1/relapse/SMN 7/85/12 9/106/4 8/80/2 10/64/2
pEFS/pOS 0.81/0.90 0.79/0.90 0.62/0.74 0.66/0.74
AML/MDS/solid tumor 5/7/0 1/1/1 2*/0/1 0/0/1*
12 year pSMN
2 2.4 +/- 0.7% 1.2 +/- 0.7%
1.2 +/- 0.8% in total
0.3 +/- 0.8 % for  non-transplanted
AML = acute myeloid leukemia; CNS = central nervous system; Dead in CR1 = dead in first remission; M2/3 BM = >5%/25% leukemic 
blasts in bone-marrow; MDS=myelodysplastic syndrome; 6MP/MTX = duration of oral 6-mercaptopurine/methotrexate maintenance therapy 
in  weeks;  pEFS/pOS  =  the  12-year  probability  of  event-free  survival  and  overall  survival,  respectively;  SR/IR/HR/VHR  = 
standard/intermediate/high/very high risk acute lymphoblastic leukemia; WBC = white blood cell count; 
1Cumulative dose in mg/m
2; 
2The 
12-year probability of developing a second malignant neoplasm; *Three of the four second malignant neoplasms (SMN) occurred after stem 




4 DNA nucleotides in leukocytes have been 
shown to be substituted with  6TGN (DNA-6TGN),
20
but it is unknown, if the risk of t-AML/MDS is related 
to the individual leukocyte DNA-6TGN levels. 
Canclusion: The relation between TPMT activity was 
not found in a recent large German BFM-study,
28 but 
this  may  reflect  both  significant  differences  between 
that study and the present Nordic study with respect to 
the  MTX/6MP  dosages  in  the  two  protocols,  and 
furthermore by the fact that only genotyping was used 
in the BFM study, whereas most patients in the Nordic 
study was classified by TPMT phenotyping. Thus, it 
remains to be explored whether TPMT genotyping or 
phenotyping is superior in predicting the risk of SMN. 
Since 2001, determination of TPMT geno-/phenotype 
has been mandatory in NOPHO protocols, and during 
the initial maintenance therapy 6MP dose is reduced to 
50  mg/m
2 for  TPMT  heterozygous  patients.  With 
longer follow-up it will be explored, if this approach 
has reduced the risk of SMN for such patients without 
compromising their low relapse rate.
17
To further increase the biological understanding of 
the  development  of  SMN,  an  international  study  on 
SMN chaired by Maria Grazia Valsecchi (AIEOP) and 
Kjeld Schmiegelow (NOPHO) on behalf of the Ponte 
di  Legno  group  has  been  initiated.  This  stuy  will 
collect data on more than 700 SMNs occuring as the 
first  event  in  children  treated  for  ALL  by  17  major 
childhood ALL groups in U.S., Europe and Asia. 
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